Laquinimod, which is being developed by Teva (TEVA +1.2%) and Sweden's Active Biotech, performed...

|About: Teva Pharmaceutical Indus... (TEVA)|By:, SA News Editor

Laquinimod, which is being developed by Teva (TEVA +1.2%) and Sweden's Active Biotech, performed well in a Phase IIa trial of patients with moderate to severe Crohns disease. The drug had a "robust, early and consistent effect on remission" and on response rates compared with a placebo. Laquinimod was also well-tolerated. (PR)